Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Tardive dyskinesia: No clinically important improvement · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Tardive dyskinesia: Deterioration of symptoms · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
General mental state: Deterioration · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Adverse events: extrapyramidal symptoms (need of antiparkinsonism drugs) · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Adverse effects: general adverse events (UKU Average change score) · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Tardive dyskinesia: Deterioration of symptoms · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia
It is very uncertain whether reduced dose of antipsychotics changes tardive dyskinesia: deterioration of symptoms compared with antipsychotic maintenance (very low certainty).
1 finding from 1 review
Leaving the study early · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tardive dyskinesia: No clinically important improvement · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether specific antipsychotic changes tardive dyskinesia: not improved to a clinically important extent compared with other drugs (very low certainty).
1 finding from 1 review
Tardive dyskinesia: Deterioration of symptoms · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether specific antipsychotic changes tardive dyskinesia: deterioration of symptoms compared with other drugs (very low certainty).
1 finding from 1 review
Mental state ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Adverse effect: any ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Adverse effect: extrapyramidal symptoms ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Leaving the study early · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether specific antipsychotic changes acceptability of the treatment: leaving the study early compared with other drugs (very low certainty).
1 finding from 1 review
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
General mental state: relapse · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia
It is very uncertain whether reduced dose of antipsychotics changes general mental state: relapse compared with antipsychotic maintenance (very low certainty).
1 finding from 1 review
RR 3 [0.16, 57.36]
1 study · 8 participants
Very low
Adverse effect: any ‐ not reported · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Adverse effect: extrapyramidal symptoms ‐ not reported · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Leaving the study early · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia
It is very uncertain whether reduced dose of antipsychotics changes acceptability of the treatment: leaving the study early compared with antipsychotic maintenance (very low certainty).
1 finding from 1 review
RR 0.33 [0.06, 1.99]
1 study · 8 participants
Very low